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Can Modern Echocardiographic
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Drug-Induced Cardiotoxicity?*
Thor Edvardsen, MD, PHD
Oslo, Norway
Trastuzumab is a humanized monoclonal antibody and is
approved for the treatment of patients with human epider-
mal growth factor receptor II (HER-2) positive breast
cancer, in the adjuvant and metastatic settings. It was
approved by the U.S. Food and Drug Administration in
1998, but the first studies were not designed to detect any
cardiac side effects. Trastuzumab has substantial therapeutic
benefits in the treatment of primary breast cancer and was
considered to be a revolutionary adjuvant drug to anthracy-
clines when 2 separate studies about its effects and side
effects were published in 2005 (1–3).
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However, the antibody has been associated with risk of
development of cardiotoxicity. This risk is further increased
when combined with anthracycline chemotherapy, which
itself is strongly associated with cardiac toxicity. Up to
one-fourth of all patients receiving trastuzumab have been
reported to develop ventricular dysfunction. Most of the
reported cardiac effects have been regarded as mild-to-
moderate, asymptomatic, reversible, and manageable by
medications (4,5).
In their paper in this issue of the Journal, Fallah-Rad et
al. (6) use tissue Doppler and strain echocardiographic
methods to reveal early signs of decreased ventricular
function in patients receiving trastuzumab.
They showed that an early decline in tissue velocity and
strain parameters was followed by a later and clinically
significant decline in left ventricular (LV) function assessed
by ejection fraction. Serum levels of troponin-T, C-reactive
protein, and brain natriuretic peptide failed to demonstrate
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Edvardsen has received honorarium from GE.LV failure. Only 42 patients were studied, and 10 of these
developed trastuzumab-mediated cardiomyopathy. A spec-
ified reduction in peak systolic myocardial velocity and peak
global strain measurements at 3 months could detect the
development of trastuzumab-mediated cardiomyopathy in
all 10 patients. Their study is important. The development
of cardiomyopathy due to a treatment regime is concerning
and might also be devastating for some patients. Therefore,
an easily available tool that can detect such development at
an early and reversible state is needed, and the present study
is reporting important results in this matter.
We should also notice that despite a discontinuation of the
antibody treatment after 6 months, LV parameters did not
recover completely in a new echocardiographic study approx-
imately 6 months after termination of trastuzumab. The
continuing reduction in LV function is further supported by
the myocardial scar found by contrast-enhanced magnetic
resonance imaging in the present study. Until now, all
trastuzumab-mediated cardiomyopathy has been regarded as
reversible, but the present results might indicate that this
assumption is not correct (4). Therefore, further studies of the
long-term effect on LV function are needed to provide a more
complete picture of trastuzumab-induced cardiotoxicity.
Improved echocardiographic tools for accurate assess-
ment of ventricular function have been launched during the
last 2 decades. Even subtle wall motion abnormalities can be
demonstrated by tissue Doppler and strain techniques (7,8).
There is no doubt that the introduction of these modern
echocardiographic techniques has made it possible to accu-
rately perform quantitative and objective measures of re-
gional ventricular function. Essential clinical decisions
should only be done after careful consideration. One must
acknowledge that a decrease in systolic myocardial velocities
of 1 cm/s from start of treatment to the next echocardio-
graphic study might be due to changes in the hemodynamic
state of each patient and might have other explanations as
well. Therefore, other echocardiographic measurements
supporting a decline in LV function should be obtained in
each patient. Generally, a combination of parameters that
demonstrates similar findings will make it easier to make a
correct decision. One of the strengths of echocardiography
is that many parameters that can accurately characterize LV
function are easily available. A decision based on only 1
measurement of myocardial velocities of the lateral LV wall
should only be done with great caution.
There are many pitfalls related to all use of echocardiog-
raphy. One obvious risk in these patients would be that low
image quality would give false low myocardial velocities,
which again can lead to wrong interpretations and wrong
decisions. Much experience with these novel techniques is
therefore needed before we jump to possible erroneous
conclusions for patients.
All echocardiographic laboratories should use these tech-
niques on a regular basis to acquire sufficient knowledge on
how they work and their strengths and weaknesses. It is not
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Until other studies confirm the findings of Fallah-Rad et al.
(6), each laboratory should earn experience in patients
receiving trastuzumab and learn how these echocardio-
graphic parameters can predict cardiotoxicity in these par-
ticular patients.
A termination of a potential life-saving treatment should
only be done after careful consideration. Therefore, cardi-
ologists and oncologists should balance the risk of recurrent
cancer against the risk of cardiovascular morbidity and
mortality when trastuzumab is given to these patients.
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